Kontigo Care Q3 2022: Stabil quarter and positive outlook - Redeye

Redeye provides its initial take on Kontigo Care’s Q3 2022 report, where sales came in at SEK7.2m (SEK6.2m), the MMR grew by 12% Y/Y, and the gross margin reached an impressive 86%. Our positive view of the company is intact; we are, however, likely to adjust our fair value range and estimates somewhat to reflect future investment needs and costs related to the drug project.

Länk till analysen i sin helhet: https://www.redeye.se/research/864161/kontigo-care-q3-2022-stabil-quarter-and-positive-outlook?utm_source=finwire&utm_medium=RSS